NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $7.49 +0.01 (+0.13%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$7.48 -0.02 (-0.20%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AUPH alerts:Sign Up Key Stats Today's Range$7.29▼$7.5050-Day Range$7.48▼$8.6452-Week Range$5.20▼$10.67Volume2.25 million shsAverage Volume1.37 million shsMarket Capitalization$1.01 billionP/E Ratio26.75Dividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 518th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth409.09% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 26.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 26.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.16.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.82% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.82% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.65 News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 33 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesAurinia Pharmaceuticals Inc News (AUPH) - Investing.com4 hours ago | investing.comAUPH - Aurinia Pharmaceuticals Inc News - MorningstarJuly 2 at 4:47 AM | morningstar.comMTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.July 3 at 2:00 AM | InvestorPlace (Ad)Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)June 30 at 6:00 AM | businesswire.comAurinia Pharmaceuticals Inc (AUPH) Announces Webcast for AUR200 Phase 1 Study Results | AUPH ...June 29, 2025 | gurufocus.comAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025June 29, 2025 | financialpost.comFAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025June 29, 2025 | businesswire.comAurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - NasdaqJune 29, 2025 | nasdaq.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH shares have decreased by 16.6% and is now trading at $7.49. View the best growth stocks for 2025 here. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings results on Monday, May, 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. The biotechnology company had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a trailing twelve-month return on equity of 14.27%. Read the conference call transcript. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional shareholders include City Center Advisors LLC (0.02%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today7/02/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$13.00 Low Stock Price Target$10.00 Potential Upside/Downside+53.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.28 Trailing P/E Ratio26.75 Forward P/E Ratio68.09 P/E GrowthN/ANet Income$5.75 million Net Margins16.11% Pretax Margin16.91% Return on Equity14.27% Return on Assets9.93% Debt Debt-to-Equity Ratio0.16 Current Ratio5.93 Quick Ratio5.26 Sales & Book Value Annual Sales$235.13 million Price / Sales4.30 Cash Flow$0.31 per share Price / Cash Flow24.25 Book Value$2.68 per share Price / Book2.79Miscellaneous Outstanding Shares135,100,000Free Float118,621,000Market Cap$1.01 billion OptionableOptionable Beta1.16 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AUPH) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.